Phibro Animal Health (PAHC) Competitors $39.72 +1.15 (+2.98%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$39.78 +0.06 (+0.16%) As of 10/17/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PAHC vs. CRSP, NUVL, AXSM, LEGN, TGTX, PCVX, MTSR, KRYS, PTCT, and ARWRShould you be buying Phibro Animal Health stock or one of its competitors? The main competitors of Phibro Animal Health include CRISPR Therapeutics (CRSP), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Legend Biotech (LEGN), TG Therapeutics (TGTX), Vaxcyte (PCVX), Metsera (MTSR), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Phibro Animal Health vs. Its Competitors CRISPR Therapeutics Nuvalent Axsome Therapeutics Legend Biotech TG Therapeutics Vaxcyte Metsera Krystal Biotech PTC Therapeutics Arrowhead Pharmaceuticals CRISPR Therapeutics (NASDAQ:CRSP) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation. Which has more volatility and risk, CRSP or PAHC? CRISPR Therapeutics has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Which has stronger earnings & valuation, CRSP or PAHC? Phibro Animal Health has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$35M179.69-$366.25M-$5.43-12.73Phibro Animal Health$1.30B1.24$48.26M$1.1833.66 Does the media prefer CRSP or PAHC? In the previous week, CRISPR Therapeutics had 24 more articles in the media than Phibro Animal Health. MarketBeat recorded 29 mentions for CRISPR Therapeutics and 5 mentions for Phibro Animal Health. CRISPR Therapeutics' average media sentiment score of 0.74 beat Phibro Animal Health's score of 0.24 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 12 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend CRSP or PAHC? CRISPR Therapeutics currently has a consensus target price of $72.59, suggesting a potential upside of 4.97%. Phibro Animal Health has a consensus target price of $28.40, suggesting a potential downside of 28.50%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 2 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.42Phibro Animal Health 2 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.13 Do institutionals and insiders hold more shares of CRSP or PAHC? 69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is CRSP or PAHC more profitable? Phibro Animal Health has a net margin of 3.73% compared to CRISPR Therapeutics' net margin of -1,229.43%. Phibro Animal Health's return on equity of 32.14% beat CRISPR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,229.43% -20.05% -17.09% Phibro Animal Health 3.73%32.14%6.89% SummaryPhibro Animal Health beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks. Get Phibro Animal Health News Delivered to You Automatically Sign up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PAHC vs. The Competition Export to ExcelMetricPhibro Animal HealthMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.61B$10.94B$6.21B$10.54BDividend Yield1.24%1.88%5.70%4.80%P/E Ratio33.6621.0385.7027.13Price / Sales1.2426.43581.70177.21Price / Cash12.1524.5537.1060.81Price / Book5.633.4112.236.52Net Income$48.26M$210.63M$3.33B$276.93M7 Day Performance9.15%0.03%1.17%1.93%1 Month Performance-0.35%-0.54%6.85%2.19%1 Year Performance65.02%-9.78%58.93%34.62% Phibro Animal Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PAHCPhibro Animal Health3.9573 of 5 stars$39.72+3.0%$28.40-28.5%+65.0%$1.61B$1.30B33.662,475Analyst ForecastCRSPCRISPR Therapeutics2.2308 of 5 stars$70.19+3.6%$71.50+1.9%+41.4%$6.16B$35M-12.93460Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionNUVLNuvalent2.8471 of 5 stars$83.85-0.4%$118.89+41.8%-10.8%$6.07BN/A-17.1140Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionAXSMAxsome Therapeutics4.7333 of 5 stars$119.94-0.3%$177.93+48.4%+37.1%$6.00B$495.03M-23.66380Positive NewsAnalyst RevisionLEGNLegend Biotech3.0853 of 5 stars$31.44-1.9%$74.22+136.1%-25.4%$5.92B$627.24M-35.732,609News CoverageAnalyst ForecastTGTXTG Therapeutics4.5107 of 5 stars$36.76+0.1%$49.00+33.3%+48.7%$5.82B$454.07M99.35290Positive NewsPCVXVaxcyte2.3414 of 5 stars$41.21-3.4%$106.25+157.8%-63.3%$5.54BN/A-10.03160News CoverageAnalyst ForecastMTSRMetseraN/A$52.50+1.2%$55.75+6.2%N/A$5.45BN/A0.0081KRYSKrystal Biotech4.7752 of 5 stars$180.57-1.5%$209.00+15.7%+6.2%$5.31B$359.21M36.70210News CoverageAnalyst ForecastGap UpPTCTPTC Therapeutics3.357 of 5 stars$64.80-0.9%$69.00+6.5%+68.7%$5.19B$1.76B9.301,410Analyst RevisionARWRArrowhead Pharmaceuticals3.8755 of 5 stars$37.50+3.8%$43.14+15.0%+73.8%$4.99B$3.55M-29.30400 Related Companies and Tools Related Companies CRSP Competitors NUVL Competitors AXSM Competitors LEGN Competitors TGTX Competitors PCVX Competitors MTSR Competitors KRYS Competitors PTCT Competitors ARWR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PAHC) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phibro Animal Health Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Phibro Animal Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
